Advances in the treatment of metastatic prostate cancer
- PMID: 37442702
- DOI: 10.1016/j.trecan.2023.06.009
Advances in the treatment of metastatic prostate cancer
Abstract
The field of metastatic prostate cancer (mPCa) has seen unprecedented therapeutic advances in the past decade. In the past 2 years, recent approvals include the triplet therapy regimens of androgen deprivation therapy (ADT), docetaxel, and an androgen receptor (AR) pathway inhibitor (ARPI) in the castration-sensitive setting and lutetium-177 vipivotide tetraxetan (177Lu-PSMA-617) and the combination of poly(ADP) ribose polymerase (PARP) inhibitors (PARPis) and ARPIs in the castration-resistant setting. With many agents currently undergoing investigation in registration trials, the therapeutic armamentarium will expand rapidly, making treatment selection and sequencing challenging. Herein, we review the landmark clinical trials ongoing or reported in the past 2 years, discuss the optimal approach to treatment selection, and provide insight into future directions.
Keywords: ARPIs; PARP inhibitors; metastatic castration-resistant prostate cancer; metastatic castration-sensitive prostate cancer; novel hormonal therapy; treatment.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests N.A. reports consultancy (lifetime association) to Astellas, AstraZeneca, Aveo, Bayer, Bristol Myers Squibb, Calithera, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead, Janssen, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics, and Seattle Genetics and reports institutional research funding from AstraZeneca, Bavarian Nordic, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, GlaxoSmithKline, Immunomedics, Janssen, Medivation, Merck, Nektar, New Link Genetics, Novartis, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon. U.S. reports consultancy to Astellas, Exelixis, Seattle Genetics, Imvax, AstraZeneca, and Sanofi and research funding to institute from Janssen, Exelixis, and Astellas/Seattle Genetics.
Similar articles
-
Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer.Curr Oncol Rep. 2024 May;26(5):488-495. doi: 10.1007/s11912-024-01509-6. Epub 2024 Apr 9. Curr Oncol Rep. 2024. PMID: 38592590 Review.
-
[Metastatic castration-resistant prostate cancer-what are rational sequential treatment options?].Urologie. 2023 Dec;62(12):1295-1301. doi: 10.1007/s00120-023-02212-3. Epub 2023 Oct 17. Urologie. 2023. PMID: 37847397 Free PMC article. Review. German.
-
Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer.Expert Rev Anticancer Ther. 2022 Nov;22(11):1163-1175. doi: 10.1080/14737140.2022.2139679. Epub 2022 Nov 3. Expert Rev Anticancer Ther. 2022. PMID: 36305305 Review.
-
Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.J Urol. 2019 May;201(5):876-885. doi: 10.1097/JU.0000000000000117. J Urol. 2019. PMID: 30747897 Review.
-
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.Eur Urol. 2018 May;73(5):696-703. doi: 10.1016/j.eururo.2017.09.022. Epub 2017 Oct 23. Eur Urol. 2018. PMID: 29074061 Clinical Trial.
Cited by
-
Squalene Epoxidase: Its Regulations and Links with Cancers.Int J Mol Sci. 2024 Mar 30;25(7):3874. doi: 10.3390/ijms25073874. Int J Mol Sci. 2024. PMID: 38612682 Free PMC article.
-
PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic Landscape.Life (Basel). 2024 Jan 30;14(2):198. doi: 10.3390/life14020198. Life (Basel). 2024. PMID: 38398706 Free PMC article. Review.
-
Diplopia and Ptosis: An Unusual Case of Prostate Cancer Metastasis to the Sphenoid Bone Treated With Palliative Radiotherapy.Cureus. 2023 Dec 15;15(12):e50566. doi: 10.7759/cureus.50566. eCollection 2023 Dec. Cureus. 2023. PMID: 38222194 Free PMC article.
-
Unlocking the role of non-coding RNAs in prostate cancer progression: exploring the interplay with the Wnt signaling pathway.Front Pharmacol. 2023 Sep 27;14:1269233. doi: 10.3389/fphar.2023.1269233. eCollection 2023. Front Pharmacol. 2023. PMID: 37829301 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous